PASSPORT

In 2006, over 45.000 European citizens died of cirrhosis of the liver and 44,000 additional citizens of liver cancer, knowing that the same year 48,700 new liver cancer cases were declared. Surgical procedures remain the options that offer the foremost success rate against such pathologies. Regretfully, surgery is not so frequent due to several limitations.

Indeed, eligibility for liver surgery is based on the minimum safety liver volume remaining after resection (standardized FLR), but this minimum value varies over time and from one patient to another according to biological and mechanical properties of the liver. Since 1996, a large set of preoperative planning software has been developed, but all of them provide only the volume of the liver before and after resection. However interesting, this limited information is not sufficient to improve the rate of surgical eligibility.

PASSPORT for Liver Surgery (PAtient specific simulation and preoperative realistic training for liver surgery) project aims at overcoming these limitations by offering a patient-specific modelling that combines anatomical, mechanical, appearance and biological preoperative modelled information in a unified model of the patient. This first complete "Virtual liver" will be developed in an Open Source Framework allowing vertical integration of biomedical data, from macroscopic to microscopic patient information.

From these models, a dynamic liver modelling will provide the patient-specific minimum safety standardized FLR in an educative and preoperative planning simulator allowing to predict the feasibility of the gesture and surgeons' ability to realise it. Thus, any patient will be able to know the risk level of a proposed therapy.

The propsed project expects to increase the rate of surgical treatment so as to save patients with a liver pathology. To reach these purposes, PASSPORT is composed of a high level partnership between internationally renowned surgical teams, leading European research teams in surgical simulation and an international leading company in surgical instrumentation.

For further information, please visit:
http://www.passport-liver.eu

Project co-ordinator:
Institut de Recherche contre les Cancers de l'Appareil Digestif (France)

Partners:

  • Universität Leipzig (Germany)
  • Technischen Universität München (Germany)
  • University College London (United Kingdom)
  • Imperial College of Science, Technology and Medicine (United Kingdom)
  • Karl Storz GmbH & Co. KG (Germany)
  • Université Louis-Pasteur (France)
  • Institut National de Recherche en Informatique et en Automatique (France)
  • Eidgenössische Technische Hochschule Zürich (Switzerland)
  • Université catholique de Louvain (Belgium)

Timetable: from 06/2008 - to 05/2011

Total cost: € 5.460.000

EC funding: € 3.640.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...